论文部分内容阅读
为了观察鼻咽癌放疗过程中血清VEGF水平的动态变化,为放射治疗联合靶向VEGF治疗鼻咽癌提供理论依据,对33例鼻咽癌初治患者在治疗前、治疗期间及治疗后每周抽血检测血清中VEGF一次,采用ELISA酶连免疫吸附实验检测血清VEGF浓度。鼻咽癌患者放疗前、放疗中和放疗后的血清VEGF值分别为(308.63±203.04)、(483.36±245.11)和(381.41±249.95)ng/L。放疗前VEGF浓度与放疗中、放疗后浓度差异有统计学意义,P值分别为0.003、0.008,而放疗中与放疗后差异无统计学意义,P=0.209;放疗期间血清VEGF最高值以放疗第3～5周为主,占血清VEGF最高值周数的63.7%。初步研究结果提示,鼻咽癌患者放疗期间血清VEGF水平较治疗前明显升高,放射治疗联合靶向VEGF治疗鼻咽癌疗效显著,值得应用。
In order to observe the dynamic changes of serum VEGF in the course of radiotherapy of nasopharyngeal carcinoma and to provide a theoretical basis for radiotherapy combined with targeted VEGF in the treatment of nasopharyngeal carcinoma, 33 patients with nasopharyngeal carcinoma before treatment, during treatment and after treatment Blood samples were collected for detection of serum VEGF once by enzyme-linked immunosorbent assay (ELISA). The serum VEGF of patients with nasopharyngeal carcinoma before radiotherapy, radiotherapy and radiotherapy were (308.63 ± 203.04), (483.36 ± 245.11) and (381.41 ± 249.95) ng / L, respectively. The difference of VEGF concentration before radiotherapy and after radiotherapy was statistically significant (P = 0.003,0.008, respectively), but there was no significant difference between radiotherapy and radiotherapy after radiotherapy (P = 0.209) 3 to 5 weeks, accounting for 63.7% of the highest number of weeks of serum VEGF. Preliminary results suggest that serum VEGF levels in patients with nasopharyngeal carcinoma during radiotherapy were significantly higher than before treatment, radiation therapy combined with targeted VEGF treatment of nasopharyngeal carcinoma significant effect, it is worth applying.